Zevra Therapeutics, Inc.
ZVRA
$8.31
$0.374.66%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 23.61M | 24.49M | 23.69M | 27.71M | 27.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.61M | 24.49M | 23.69M | 27.71M | 27.46M |
| Cost of Revenue | 7.42M | 7.28M | 5.12M | 2.22M | 2.17M |
| Gross Profit | 16.20M | 17.21M | 18.57M | 25.49M | 25.29M |
| SG&A Expenses | 54.92M | 54.18M | 43.79M | 37.79M | 35.09M |
| Depreciation & Amortization | 6.24M | 5.39M | 3.85M | 2.30M | 772.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 110.62M | 111.23M | 98.49M | 84.97M | 77.07M |
| Operating Income | -87.00M | -86.74M | -74.80M | -57.26M | -49.60M |
| Income Before Tax | -90.14M | -89.66M | -66.63M | -49.42M | -46.05M |
| Income Tax Expenses | 15.37M | 0.00 | 177.00K | 33.00K | 0.00 |
| Earnings from Continuing Operations | -105.51 | -89.66 | -66.81 | -49.45 | -46.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -105.51M | -89.66M | -66.81M | -49.45M | -46.05M |
| EBIT | -87.00M | -86.74M | -74.80M | -57.26M | -49.60M |
| EBITDA | -80.61M | -81.22M | -70.83M | -54.77M | -48.60M |
| EPS Basic | -2.24 | -2.08 | -1.69 | -1.29 | -1.27 |
| Normalized Basic EPS | -1.22 | -1.30 | -1.05 | -0.81 | -0.81 |
| EPS Diluted | -2.24 | -2.08 | -1.69 | -1.29 | -1.27 |
| Normalized Diluted EPS | -1.22 | -1.30 | -1.05 | -0.81 | -0.81 |
| Average Basic Shares Outstanding | 184.96M | 170.20M | 157.12M | 149.12M | 141.81M |
| Average Diluted Shares Outstanding | 184.96M | 170.20M | 157.12M | 149.12M | 141.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
